195 related articles for article (PubMed ID: 34789774)
21. Noninvasive KRAS mutation estimation in colorectal cancer using a deep learning method based on CT imaging.
He K; Liu X; Li M; Li X; Yang H; Zhang H
BMC Med Imaging; 2020 Jun; 20(1):59. PubMed ID: 32487083
[TBL] [Abstract][Full Text] [Related]
22. Positron emission tomography/computed tomography and biomarkers for early treatment response evaluation in metastatic colon cancer.
Engelmann BE; Loft A; Kjær A; Nielsen HJ; Gerds TA; Benzon EV; Brünner N; Christensen IJ; Hansson SH; Holländer NH; Kristensen MH; Löfgren J; Markova E; Sloth C; Højgaard L
Oncologist; 2014 Feb; 19(2):164-72. PubMed ID: 24451199
[TBL] [Abstract][Full Text] [Related]
23. Gene expression of vascular endothelial growth factor A, thymidylate synthase, and tissue inhibitor of metalloproteinase 3 in prediction of response to bevacizumab treatment in colorectal cancer patients.
Watanabe T; Kobunai T; Yamamoto Y; Matsuda K; Ishihara S; Nozawa K; Iinuma H; Ikeuchi H
Dis Colon Rectum; 2011 Aug; 54(8):1026-35. PubMed ID: 21730794
[TBL] [Abstract][Full Text] [Related]
24. Prognostic value of different CT measurements in early therapy response evaluation in patients with metastatic colorectal cancer.
Huellner MW; Hennedige TP; Winterhalder R; Zander T; Venkatesh SK; Yong WP; Soo RA; Seifert B; Treumann TC; Strobel K; Veit-Haibach P
Cancer Imaging; 2012 May; 12(1):212-24. PubMed ID: 22750105
[TBL] [Abstract][Full Text] [Related]
25. Early hypertension and neutropenia are predictors of treatment efficacy in metastatic colorectal cancer patients administered FOLFIRI and vascular endothelial growth factor inhibitors as second-line chemotherapy.
Osumi H; Shinozaki E; Ooki A; Wakatsuki T; Kamiimabeppu D; Sato T; Nakayama I; Ogura M; Takahari D; Chin K; Yamaguchi K
Cancer Med; 2021 Jan; 10(2):615-625. PubMed ID: 33347731
[TBL] [Abstract][Full Text] [Related]
26. Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab.
Yen LC; Uen YH; Wu DC; Lu CY; Yu FJ; Wu IC; Lin SR; Wang JY
Ann Surg; 2010 Feb; 251(2):254-60. PubMed ID: 20010090
[TBL] [Abstract][Full Text] [Related]
27. Effectiveness and safety of aflibercept for metastatic colorectal cancer: retrospective review within an early access program in Spain.
Feliu J; Díez de Corcuera I; Manzano JL; Valladares-Ayerbes M; Alcaide J; García García T; Vera R; Sastre J
Clin Transl Oncol; 2017 Apr; 19(4):498-507. PubMed ID: 27718155
[TBL] [Abstract][Full Text] [Related]
28. Predictive value of VEGF gene polymorphisms for metastatic colorectal cancer patients receiving first-line treatment including fluorouracil, irinotecan, and bevacizumab.
Formica V; Palmirotta R; Del Monte G; Savonarola A; Ludovici G; De Marchis ML; Grenga I; Schirru M; Guadagni F; Roselli M
Int J Colorectal Dis; 2011 Feb; 26(2):143-51. PubMed ID: 21188390
[TBL] [Abstract][Full Text] [Related]
29. A randomized phase 3 study on the optimization of the combination of bevacizumab with FOLFOX/OXXEL in the treatment of patients with metastatic colorectal cancer-OBELICS (Optimization of BEvacizumab scheduLIng within Chemotherapy Scheme).
Avallone A; Piccirillo MC; Aloj L; Nasti G; Delrio P; Izzo F; Di Gennaro E; Tatangelo F; Granata V; Cavalcanti E; Maiolino P; Bianco F; Aprea P; De Bellis M; Pecori B; Rosati G; Carlomagno C; Bertolini A; Gallo C; Romano C; Leone A; Caracò C; de Lutio di Castelguidone E; Daniele G; Catalano O; Botti G; Petrillo A; Romano GM; Iaffaioli VR; Lastoria S; Perrone F; Budillon A
BMC Cancer; 2016 Feb; 16():69. PubMed ID: 26857924
[TBL] [Abstract][Full Text] [Related]
30. Gene expression profile predictive of response to chemotherapy in metastatic colorectal cancer.
Estevez-Garcia P; Rivera F; Molina-Pinelo S; Benavent M; Gómez J; Limón ML; Pastor MD; Martinez-Perez J; Paz-Ares L; Carnero A; Garcia-Carbonero R
Oncotarget; 2015 Mar; 6(8):6151-9. PubMed ID: 25730906
[TBL] [Abstract][Full Text] [Related]
31. Deep learning-assisted magnetic resonance imaging prediction of tumor response to chemotherapy in patients with colorectal liver metastases.
Zhu HB; Xu D; Ye M; Sun L; Zhang XY; Li XT; Nie P; Xing BC; Sun YS
Int J Cancer; 2021 Apr; 148(7):1717-1730. PubMed ID: 33284998
[TBL] [Abstract][Full Text] [Related]
32. Use of early tumor shrinkage to predict long-term outcome in metastatic colorectal cancer treated with cetuximab.
Piessevaux H; Buyse M; Schlichting M; Van Cutsem E; Bokemeyer C; Heeger S; Tejpar S
J Clin Oncol; 2013 Oct; 31(30):3764-75. PubMed ID: 24043732
[TBL] [Abstract][Full Text] [Related]
33. Prognostic importance of tumor location and anti-EGFR therapy in patients with K-RAS wild type metastatic colorectal cancer.
Kucukoner M; Oztekin E; Akdeniz N; Morkuzu S; Yerlikaya H; Urakci Z; Kaplan MA; Isikdogan A
J BUON; 2019; 24(4):1501-1506. PubMed ID: 31646798
[TBL] [Abstract][Full Text] [Related]
34. 3'-Deoxy-3'-18F-fluorothymidine PET for the early prediction of response to leucovorin, 5-fluorouracil, and oxaliplatin therapy in patients with metastatic colorectal cancer.
Hong YS; Kim HO; Kim KP; Lee JL; Kim HJ; Lee SJ; Lee SJ; Oh SJ; Kim JS; Ryu JS; Moon DH; Kim TW
J Nucl Med; 2013 Aug; 54(8):1209-16. PubMed ID: 23804324
[TBL] [Abstract][Full Text] [Related]
35. Predictive Value of Early Tumor Shrinkage and Density Reduction of Lung Metastases in Patients With Metastatic Colorectal Cancer Treated With Regorafenib.
Vanwynsberghe H; Verbeke X; Coolen J; Van Cutsem E
Clin Colorectal Cancer; 2017 Dec; 16(4):377-380. PubMed ID: 28454726
[TBL] [Abstract][Full Text] [Related]
36. FOLFIRI and sunitinib as first-line treatment in metastatic colorectal cancer patients with liver metastases--a CESAR phase II study including pharmacokinetic, biomarker, and imaging data.
Mross K; Scheulen M; Strumberg D; Kuhlmann J; Kanefendt F; Sörgel F; Jaehde U; Burkholder I; Moritz B; Büchert M
Int J Clin Pharmacol Ther; 2014 Aug; 52(8):642-52. PubMed ID: 24800922
[TBL] [Abstract][Full Text] [Related]
37. Monitoring metabolic response using FDG PET-CT during targeted therapy for metastatic colorectal cancer.
Woff E; Hendlisz A; Garcia C; Deleporte A; Delaunoit T; Maréchal R; Holbrechts S; Van den Eynde M; Demolin G; Vierasu I; Lhommel R; Gauthier N; Guiot T; Ameye L; Flamen P
Eur J Nucl Med Mol Imaging; 2016 Sep; 43(10):1792-801. PubMed ID: 27072811
[TBL] [Abstract][Full Text] [Related]
38. Can carcinoembryonic antigen replace computed tomography in response evaluation of metastatic colorectal cancer?
Hermunen K; Lantto E; Poussa T; Haglund C; Österlund P
Acta Oncol; 2018 Jun; 57(6):750-758. PubMed ID: 29388498
[TBL] [Abstract][Full Text] [Related]
39. A deep learning risk prediction model for overall survival in patients with gastric cancer: A multicenter study.
Zhang L; Dong D; Zhang W; Hao X; Fang M; Wang S; Li W; Liu Z; Wang R; Zhou J; Tian J
Radiother Oncol; 2020 Sep; 150():73-80. PubMed ID: 32540334
[TBL] [Abstract][Full Text] [Related]
40. Emergence of RAS mutations in patients with metastatic colorectal cancer receiving cetuximab-based treatment: a study protocol.
Chen SH; Tsai HL; Jiang JK; Sung YC; Huang CW; Yeh YM; Chen LT; Wang JY
BMC Cancer; 2019 Jun; 19(1):640. PubMed ID: 31253124
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
